ML-004 Phase 2 IRIS Trial Misses Primary Endpoint but Shows Strong Efficacy in ASD Irritability

summarizeSummary

MapLight Therapeutics' ML-004 Phase 2 IRIS trial missed its primary endpoint for social communication in ASD but showed strong, differentiated efficacy in reducing irritability in adolescents, paving the way for a new development path.

check_boxKey Events · Product Development and Regulatory · MPLT

• ML-004 Phase 2 IRIS Trial Results

  The study did not meet its primary endpoint for social communication deficits in autism spectrum disorder (ASD).

• Strong Efficacy in Irritability

  ML-004 showed clinically meaningful improvement in irritability in adolescents with moderate-to-severe baseline irritability, with effect sizes of 1.33 (caregiver-reported) and 1.08 (clinician-rated).

• Favorable Safety Profile

  The drug was well-tolerated with no severe adverse events, no extrapyramidal symptoms, and lower weight gain compared to placebo, offering differentiation from current treatments.

• New Development Path

  MapLight plans to engage with the FDA for End-of-Phase 2 discussions to pursue ML-004 for irritability in ASD, an area of high unmet medical need.

auto_awesomeAnalysis · MPLT · Life Sciences

MapLight Therapeutics announced mixed Phase 2 results for ML-004 in autism spectrum disorder. While the study did not meet its primary endpoint for social communication deficits, it demonstrated clinically meaningful improvements in irritability in adolescents with moderate-to-severe baseline irritability. The drug also showed a favorable safety profile, notably with no extrapyramidal events and lower weight gain compared to placebo, offering a potential differentiation from existing antipsychotics. The company plans to engage with the FDA to pursue development for this indication, which has a high unmet medical need.